Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
Entera Bio announced an additional late-breaking poster presentation at the ASBMR 2026 Annual Meeting (Oct 9-12, Boston) outlining the study design for its planned single Phase 3 registrational trial of EB613, an oral PTH(1-34) tablet for postmenopausal osteoporosis. The presentation, led by osteoporosis authority Dr. Felicia Cosman of Columbia University, joins the company's previously accepted Plenary Poster of Phase 2 data, in which the 161-patient, 6-month study met all biomarker and BMD endpoints.
Key figures
- Drug Name
- EB613 (oral PTH(1-34) tablet)
- Phase Of Trial
- Phase 3
- Phase2 patients
- 161
- Presentation number
- Sun-522
- Phase2 duration months
- 6
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.